Compare Mercadolibre Inc (MELI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs Sana Biotechnology Inc — how do they compare? Mercadolibre Inc trades at $1,835.72 (market cap $91.96B), while Sana Biotechnology Inc trades at $3.13 (market cap $876.62M). The key difference: Mercadolibre Inc is far larger — about 104.9× Sana Biotechnology Inc's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| MELI | SANA | |
|---|---|---|
Market Cap | $91.96B | $876.62M |
Sector | Consumer Cyclical | Health |
52-Week High | $2.51K | $5.92 |
52-Week Low | $1.55K | $2.68 |
Enterprise Value | $98.85B | $850.81M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,843, up 1.6% over 24 hours, with a mixed technical picture showing bearish signals but strong analyst support. The company reported robust revenue growth to $28.89 billion in 2025, though net income margins have compressed to 6.04% amid heavy investment. Recent news highlights strategic focus on expanding cross-border trade and fintech services in Latin America, driving investor optimism despite near-term margin pressures.
Outlook remains positive given dominant market position and long-term growth initiatives, but risks include elevated valuation multiples, competitive intensity, and ongoing legal scrutiny. Wall Street consensus is strongly bullish with a $2,230 price target, suggesting 21% upside from current levels if execution continues.
Sana Biotechnology (SANA) trades at $3.13, down 0.63% on the day, with a bearish technical signal from moving averages and oscillators. The company reported a net loss of $244.17 million in 2025 and negative cash flow, though recent news highlights clinical progress in cell therapy. Analyst consensus is strongly bullish with 82% buy ratings, but financials show significant losses and high P/B of 7.35.
Outlook hinges on clinical success driving future revenue, but high cash burn and negative ROE pose near-term risks. Investment opportunity lies in pipeline milestones, yet volatility and funding needs require caution for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
